innoVitro is a german CRO, providing human-based cardiac risk screening services for Pharma, Biotech and Academia worldwide. Screening parameters encompass structural and functional parameters analysed with a high throughput 96-well hybrid system consisting of the CardioExcyte and the proprietary FLEXcyte 96 technology. Either one or both technologies can be applied for addressing drug-induced changes of healthy or diseased hiPSC-cardiomyocytes regarding morphological and contractile changes.